Nuvectis Pharma Inc
NVCT
Company Profile
Business description
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Contact
1 Bridge Plaza
2nd Floor, Suite 275
Fort LeeNJ07024
USAT: +1 201 614-3150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Bapcor earnings: Under review amid sharply lower profits and a massively dilutive equity raise
Our view of results.
stocks
Earnings winners: WOW, WTC and FMG set the tone
The ASX companies that closed out earnings season with a bang.
stocks
Do dividends build or limit wealth creation?
In this episode of Investing Compass, we talk to James Gruber about why he dislikes dividend stocks.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,435.60 | 15.10 | 0.16% |
| CAC 40 | 8,580.75 | 40.18 | -0.47% |
| DAX 40 | 25,284.26 | 4.76 | -0.02% |
| Dow JONES (US) | 48,977.92 | 521.28 | -1.05% |
| FTSE 100 | 10,910.55 | 63.85 | 0.59% |
| HKSE | 26,630.54 | 249.52 | 0.95% |
| NASDAQ | 22,668.21 | 210.17 | -0.92% |
| Nikkei 225 | 58,850.27 | 96.88 | 0.16% |
| NZX 50 Index | 13,722.97 | 52.26 | 0.38% |
| S&P 500 | 6,878.88 | 29.98 | -0.43% |
| S&P/ASX 200 | 9,198.60 | 16.90 | 0.18% |
| SSE Composite Index | 4,162.88 | 16.25 | 0.39% |